XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
OHSU Knight Cancer Institute
City of Hope Medical Center
OHSU Knight Cancer Institute
University of Pittsburgh